These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19926405)

  • 61. Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study.
    Valerio H; Conway A; Alavi M; Treloar C; Silk D; Murray C; Henderson C; Amin J; Read P; Degenhardt L; Christmass M; Montebello M; Dore GJ; Grebely J;
    Int J Drug Policy; 2022 Dec; 110():103876. PubMed ID: 36240657
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin.
    Toyoda H; Kumada T; Shimada N; Takaguchi K; Ide T; Sata M; Ginba H; Matsuyama K; Izumi N
    BMC Infect Dis; 2012 Nov; 12():324. PubMed ID: 23181537
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort.
    Vogel M; Dominguez S; Bhagani S; Azwa A; Page E; Guiguet M; Valantin MA; Katlama C; Rockstroh JK; Nelson M
    Antivir Ther; 2010; 15(2):267-79. PubMed ID: 20386082
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.
    Akiyama MJ; Cleland CM; Lizcano JA; Cherutich P; Kurth AE
    Lancet Infect Dis; 2019 Nov; 19(11):1255-1263. PubMed ID: 31540840
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Peginterferon/ribavirin treatment achieves a higher compliance rate than interferon/ribavirin combination in patients chronically infected with HCV on methadone maintenance.
    Dimitroulopoulos D; Petroulaki E; Manolakopoulos S; Anagnostou O; Tsaklakidou D; Xinopoulos D; Tsamakidis K; Tzourmakliotis D; Paraskevas E
    Eur J Gastroenterol Hepatol; 2009 Dec; 21(12):1407-12. PubMed ID: 19916203
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
    Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
    Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.
    Gill U; Aziz H; Gill ML
    Int J Infect Dis; 2013 Nov; 17(11):e1017-21. PubMed ID: 23896656
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin.
    Gilleece YC; Browne RE; Asboe D; Atkins M; Mandalia S; Bower M; Gazzard BG; Nelson MR
    J Acquir Immune Defic Syndr; 2005 Sep; 40(1):41-6. PubMed ID: 16123680
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial.
    Deterding K; Grüner N; Buggisch P; Wiegand J; Galle PR; Spengler U; Hinrichsen H; Berg T; Potthoff A; Malek N; Großhennig A; Koch A; Diepolder H; Lüth S; Feyerabend S; Jung MC; Rogalska-Taranta M; Schlaphoff V; Cornberg M; Manns MP; Wedemeyer H;
    Lancet Infect Dis; 2013 Jun; 13(6):497-506. PubMed ID: 23523674
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.
    Dominguez S; Ghosn J; Valantin MA; Schruniger A; Simon A; Bonnard P; Caumes E; Pialoux G; Benhamou Y; Thibault V; Katlama C
    AIDS; 2006 May; 20(8):1157-61. PubMed ID: 16691067
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.
    Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011644. PubMed ID: 28285495
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon.
    Schmidt SC; Bahra M; Bayraktar S; Berg T; Schmeding M; Pratschke J; Neuhaus P; Neumann U
    Dig Dis Sci; 2010 Jul; 55(7):2063-9. PubMed ID: 19798575
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
    Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
    Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
    J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.
    Turner KM; Hutchinson S; Vickerman P; Hope V; Craine N; Palmateer N; May M; Taylor A; De Angelis D; Cameron S; Parry J; Lyons M; Goldberg D; Allen E; Hickman M
    Addiction; 2011 Nov; 106(11):1978-88. PubMed ID: 21615585
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prevalence of hepatitis C virus infection and associated factors among male illicit drug users in Cuiabá, Mato Grosso, Brazil.
    Novais AC; Lopes CL; Reis NR; Silva AM; Martins RM; Souto FJ
    Mem Inst Oswaldo Cruz; 2009 Sep; 104(6):892-6. PubMed ID: 19876562
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy.
    Taylor LE; Bowman SE; Chapman S; Zaller N; Stein MD; Cioe PA; Maynard MA; McGovern BH
    Drug Alcohol Depend; 2011 Jul; 116(1-3):233-7. PubMed ID: 21177046
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hepatitis C treatment uptake and adherence among injecting drug users in the Czech Republic.
    Mravčík V; Strada L; Reimer J; Schulte B
    Epidemiol Mikrobiol Imunol; 2014 Nov; 63(4):265-9. PubMed ID: 25523218
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Failure of hepatitis C therapy in HIV-coinfected drug users is not due to a shift in hepatitis C virus genotype.
    Soriano V; Ramos B; Nunez M; Barreiro P; Maida I; Garcia-Samaniego J; Gonzalez-Lahoz J
    J Infect Dis; 2005 Oct; 192(7):1245-8. PubMed ID: 16136468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.